Comparative CD4 T-cell responses of reverse transcriptase inhibitor therapy with or without nelfinavir matched for viral exposure

HIV Clinical Trials

Volumn 2, Issue 2, 2001, Pages 160-170

  Kravcik, S ^a   Magill, A ^a   Sanghvi, B ^a   Ogden, R ^a   Cameron, D W ^a   Lewis, R ^a   Yu, G ^a   Badley, A D ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

CD4; HIV; Immune reconstitution; Protease inhibitor

Indexed keywords

CD4 ANTIGEN; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EXPOSURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STATISTICAL MODEL; T LYMPHOCYTE SUBPOPULATION; TIME; VIRUS LOAD;

EID: 0035050209     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/F45L-FDKK-Y48N-N2BT     Document Type: Article

References (48)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus syndrome
2. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group
3. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
4. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir
5. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease
6. Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir
7. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine
8. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy
9. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
10. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART)
11. Improvement in CD4+ cell counts despite persistently detectable HIV load
12. CD8+ lymphocyte responses to antiretroviral therapy of HIV infection
13. Failure isn't what it used to be...but neither is success
14. Correlation between human immunodeficiency virus genotypic resistance and virologic response in patients receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine
15. A randomized phase II dose range-finding study of the HIV protease inhibitor Viracept as monotherapy in HIV positive patients
16. Analysis of long-term virologic data from the Viracept 511 protocol using 3 HIV-RNA assays [Abstract 372]
17. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection
18. A simple relationship between viral load and survival time in HIV-1 infection
19. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study
20. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
21. HIV-1 messenger RNA in peripheral blood mononuclear cells as an early marker of risk for progression to AIDS
22. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS
23. Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: Relationships to host factors, cellular restoration and virologic end points
24. Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen
25. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: Results from the EuroSIDA Study
26. Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen
27. Mechanisms of HIV associated lymphocyte apoptosis
28. Decreased HIV-associated T cell apoptosis by HIV protease inhibitors
29. Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo
30. Dynamic correlation of apoptosis and immune activation during treatment of HIV infection
31. In vivo analysis of Fas/FasL interactions in HIV-infected patients
32. Effect of combination antiretroviral therapy upon rectal mucosal HIV RNA burden and mononuclear cell apoptosis
33. Anti-retroviral therapy reverses HIV-associated abnormalities in lymphocyte apoptosis
34. Early T-cell apoptosis and Fas expression during antiretroviral therapy in individuals infected with human immunodeficiency virus-1
35. Antiviral drugs
36. Active human immunodeficiency virus protease is required for viral infectivity
37. Characterization of human immunodeficiency virus gag/pol gene products expressed by recombinant vaccinia viruses
38. The HIV-1 protease as a therapeutic target for AIDS
39. Effect of two novel inhibitors of the human immunodeficiency virus protease on the maturation of the HIV gag and gag-pol polyproteins
40. Removal of human immunodeficiency virus type 1 (HIV-1) protease inhibitors from preparations of immature HIV-1 virions does not result in an increase in infectivity or the appearance of mature morphology
41. Correlation between changes in plasma HIV RNA levels and in plasma infectivity in response to antiretroviral therapy
42. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1
43. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors
44. Impaired infectivity of HIV-1 after a single point mutation in the POL gene to escape the effect of a protease inhibitor in vitro
45. Loss of viral fitness associated with multiple gag and gagpol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo
46. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients
47. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy
48. Effect of therapy cessation during a discordant response to HAART: Implications for scheduled therapeutic interruptions